APA (7th ed.) Citation

CK, M., Z, W., K, K., R, G., V, W., LM, M., . . . KT, F. (2025). Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(23), 4912. https://doi.org/10.1158/1078-0432.CCR-24-3431

Chicago Style (17th ed.) Citation

CK, McCourt, et al. "Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 31, no. 23 (2025): 4912. https://doi.org/10.1158/1078-0432.CCR-24-3431.

MLA (9th ed.) Citation

CK, McCourt, et al. "Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 31, no. 23, 2025, p. 4912, https://doi.org/10.1158/1078-0432.CCR-24-3431.